Results 101 to 110 of about 33,638 (296)

JAK-2 inhibitors and allogeneic transplant in myelofibrosis [PDF]

open access: yes, 2015
7The activation of the JAK1/JAK2 pathway plays a crucial role in the pathogenesis of myelofibrosis. Treatment with the JAK2 inhibitor ruxolitinib demonstrated to reduce splenomegaly and symptoms in patients affected by myelofibrosis, leading to a ...
Cigana, C   +6 more
core  

Are we ignoring sex differences in haematological malignancies? A call for improved reporting

open access: yesBritish Journal of Haematology, EarlyView.
A large body of data indicates that there are sex differences in the incidence of haematological malignancies, their clinical presentation and molecular profiles, and possibly also their aetiologies. Furthermore, sex‐related differences exist in treatment tolerability and outcomes.
Ora Paltiel   +2 more
wiley   +1 more source

Myelofibrosis [PDF]

open access: yesProceedings of the Royal Society of Medicine, 1952
R B, FRANKS, J S, RICHARDSON
openaire   +2 more sources

The degree of anisocytosis predicts survival in patients with primary myelofibrosis [PDF]

open access: yes, 2016
Introduction: Red cell distribution width (RDW) provides a quantitative measure of anisocytosis and it is associated with the presence of subclinical systemic inflammation and a poor outcome in a variety of diseases when elevated.
Hariš, Višnja   +10 more
core   +1 more source

Non-driver mutations in myeloproliferative neoplasm-associated myelofibrosis

open access: yesJournal of Hematology & Oncology, 2017
We studied non-driver mutations in 62 subjects with myeloproliferative neoplasm (MPN)-associated myelofibrosis upon diagnosis, including 45 subjects with primary myelofibrosis (PMF) and 17 with post-polycythemia vera or post-essential thrombocythemia ...
Bing Li   +11 more
doaj   +1 more source

Ruxolitinib in the treatment of polycythemia vera: patient selection and special considerations. [PDF]

open access: yes, 2016
The discovery of JAK2 V617F mutation in the mid-2000s started to fill the gap between clinical presentation of polycythemia vera (PV), first described by Vaquez at the end of the 19th century, and spontaneous erythroid colony formation, reported by ...
Alberio, L., Blum, S., Martins, F.
core   +2 more sources

WHO Reporting System for Lung Cytopathology: Insights Into the Insufficient/Inadequate/Non‐Diagnostic, Atypical and Suspicious for Malignancy Categories and How to Use Them

open access: yesCytopathology, EarlyView.
The WHO System is an international effort to standardise category definitions, establish the key diagnostic cytopathological features of entities of the lung, propose the best use of ancillary tests in lung specimens, encourage the use of standardised pathology reports containing essential components in an integrated report and propose estimates of the
Zahra Maleki, Sule Canberk, Andrew Field
wiley   +1 more source

Extramedullary myeloid tumors in primary myelofibrosis [PDF]

open access: bronze, 1965
Philip Lieberman   +2 more
openalex   +1 more source

Pathogenic variants in chromatin‐related genes: Linking immune dysregulation to neuroregression and acute neuropsychiatric disorders

open access: yesDevelopmental Medicine &Child Neurology, EarlyView.
Chromatin machinery influences how DNA is ‘wrapped’ around histones in the nucleosome of immune and brain cells. Plain language summary: https://onlinelibrary.wiley.com/doi/10.1111/dmcn.16299 Abstract We report eight children with de novo pathogenic DNA variants in chromatin‐related genes: MORC2, CHD7, KANSL1, KMT2D, ZMYND11, HIST1HIE, EP300, and KMT2B.
Russell C. Dale   +14 more
wiley   +1 more source

Use of Testosterone and Busulfan in the Treatment of Myelofibrosis with Myeloid Metaplasia [PDF]

open access: bronze, 1964
Richard T. Silver   +3 more
openalex   +1 more source

Home - About - Disclaimer - Privacy